DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,712,973 | +1.6% | 10,935 | -1.7% | 0.64% | +1.6% |
Q2 2023 | $2,670,000 | +21.0% | 11,125 | +27.1% | 0.64% | +17.4% |
Q1 2023 | $2,206,358 | -25.5% | 8,754 | -21.5% | 0.54% | +3.0% |
Q4 2022 | $2,960,760 | -4.1% | 11,155 | -6.7% | 0.52% | -9.6% |
Q3 2022 | $3,088,000 | -1.1% | 11,954 | -2.9% | 0.58% | -0.3% |
Q2 2022 | $3,122,000 | -13.5% | 12,313 | +0.1% | 0.58% | +5.2% |
Q1 2022 | $3,609,000 | -6.0% | 12,303 | +5.4% | 0.55% | -9.9% |
Q4 2021 | $3,839,000 | +7.8% | 11,668 | -0.3% | 0.62% | -5.5% |
Q3 2021 | $3,561,000 | +12.5% | 11,698 | -0.8% | 0.65% | +17.3% |
Q2 2021 | $3,164,000 | +22.0% | 11,789 | +2.3% | 0.56% | +12.1% |
Q1 2021 | $2,593,000 | +34.5% | 11,519 | +32.8% | 0.50% | +19.3% |
Q4 2020 | $1,928,000 | -3.6% | 8,677 | -6.6% | 0.42% | -20.5% |
Q3 2020 | $2,001,000 | +23.8% | 9,291 | +1.6% | 0.52% | +25.5% |
Q2 2020 | $1,616,000 | +253.6% | 9,141 | +177.0% | 0.42% | +205.9% |
Q1 2020 | $457,000 | – | 3,300 | – | 0.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |